Stockreport

Enanta: Maintaining Buy Rating Based On Zelicapavir Potential In RSV Development [Seeking Alpha]

Enanta Pharmaceuticals, Inc.  (ENTA) 
Last enanta pharmaceuticals, inc. earnings: 2/6 04:00 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.enanta.com/investor-overview
PDF Company's pipeline strength is supported by EDP-323's positive prophylaxis data and robust preclinical immunology programs targeting STAT6 and KIT pathways. The compa [Read more]